JP2021512920A - 耳鳴、急性感音性難聴、メニエール病、トゥレット症候群、注意欠陥多動性障害、および嗜癖の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 - Google Patents

耳鳴、急性感音性難聴、メニエール病、トゥレット症候群、注意欠陥多動性障害、および嗜癖の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 Download PDF

Info

Publication number
JP2021512920A
JP2021512920A JP2020542858A JP2020542858A JP2021512920A JP 2021512920 A JP2021512920 A JP 2021512920A JP 2020542858 A JP2020542858 A JP 2020542858A JP 2020542858 A JP2020542858 A JP 2020542858A JP 2021512920 A JP2021512920 A JP 2021512920A
Authority
JP
Japan
Prior art keywords
amino
carboxylic acid
pharmaceutically acceptable
acceptable salt
difluoromethylenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512920A5 (https=
JPWO2019157273A5 (https=
Inventor
マシュー・デューリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2021512920A publication Critical patent/JP2021512920A/ja
Publication of JP2021512920A5 publication Critical patent/JP2021512920A5/ja
Publication of JPWO2019157273A5 publication Critical patent/JPWO2019157273A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020542858A 2018-02-08 2019-02-08 耳鳴、急性感音性難聴、メニエール病、トゥレット症候群、注意欠陥多動性障害、および嗜癖の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 Pending JP2021512920A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862628020P 2018-02-08 2018-02-08
US62/628,020 2018-02-08
US201862628541P 2018-02-09 2018-02-09
US62/628,541 2018-02-09
PCT/US2019/017201 WO2019157273A1 (en) 2018-02-08 2019-02-08 Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction

Publications (3)

Publication Number Publication Date
JP2021512920A true JP2021512920A (ja) 2021-05-20
JP2021512920A5 JP2021512920A5 (https=) 2022-02-15
JPWO2019157273A5 JPWO2019157273A5 (https=) 2022-02-15

Family

ID=67475310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542858A Pending JP2021512920A (ja) 2018-02-08 2019-02-08 耳鳴、急性感音性難聴、メニエール病、トゥレット症候群、注意欠陥多動性障害、および嗜癖の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用

Country Status (10)

Country Link
US (1) US10653652B2 (https=)
EP (1) EP3735237A4 (https=)
JP (1) JP2021512920A (https=)
KR (3) KR20210007948A (https=)
CN (1) CN112261938A (https=)
AU (1) AU2019216742B2 (https=)
CA (1) CA3090258A1 (https=)
IL (1) IL276287A (https=)
MX (1) MX2020008359A (https=)
WO (1) WO2019157273A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE061437T2 (hu) 2015-10-23 2023-06-28 Navitor Pharm Inc A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai
US10912750B2 (en) 2017-04-26 2021-02-09 Navitor Pharmaceuticals, Inc. Modulators of Sestrin-GATOR2 interaction and uses thereof
US11771671B2 (en) 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
MX2020010302A (es) * 2018-03-29 2021-01-08 Ovid Therapeutics Inc Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
CN113164414A (zh) 2018-10-24 2021-07-23 纳维托制药有限公司 多晶型化合物和其用途
CA3156436A1 (en) * 2019-11-01 2021-05-06 Steven LEVENTER Methods of treatment using an mtorc1 modulator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062942A2 (en) * 2015-10-09 2017-04-13 Northwestern University (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US6656172B1 (en) * 2002-09-27 2003-12-02 Medtronic, Inc. Method for treating severe tinnitus
EP1954316A1 (en) * 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
CA2790820A1 (en) 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
WO2012042314A1 (en) 2010-10-02 2012-04-05 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US20140315992A1 (en) 2011-07-07 2014-10-23 The Children's Hospital Of Philadelphia Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism
EP2790686B1 (en) 2011-12-12 2021-03-10 Zilentin Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
EP2806867A4 (en) * 2012-01-27 2015-09-02 Catalyst Pharmaceutical Partners Inc METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS
EP4692048A3 (en) 2017-02-08 2026-04-01 Ovid Therapeutics Inc. Methods of treating cdkl5 disorders with the compound ov329

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062942A2 (en) * 2015-10-09 2017-04-13 Northwestern University (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JARO JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY, vol. 8, JPN6022050534, 2007, pages 105 - 118, ISSN: 0004932049 *
JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 140, no. 6, JPN6022050532, 2018, pages 2151 - 2165, ISSN: 0004932048 *
NEUROBIOLOGY OF AGING, vol. 56, JPN6022050536, 2017, pages 87 - 99, ISSN: 0004932050 *

Also Published As

Publication number Publication date
KR20250167147A (ko) 2025-11-28
WO2019157273A1 (en) 2019-08-15
KR20240154700A (ko) 2024-10-25
EP3735237A4 (en) 2021-03-17
CA3090258A1 (en) 2019-08-15
IL276287A (en) 2020-09-30
AU2019216742A1 (en) 2020-08-13
CN112261938A (zh) 2021-01-22
KR20210007948A (ko) 2021-01-20
US20190240174A1 (en) 2019-08-08
EP3735237A1 (en) 2020-11-11
AU2019216742B2 (en) 2024-05-09
US10653652B2 (en) 2020-05-19
MX2020008359A (es) 2020-11-24

Similar Documents

Publication Publication Date Title
JP2021512920A (ja) 耳鳴、急性感音性難聴、メニエール病、トゥレット症候群、注意欠陥多動性障害、および嗜癖の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用
Natarajan Surendar et al. A comparative evaluation of intrnasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study
ES2367868T3 (es) Uso de memantina (namenda) para tratar el autismo, la compulsividad y la impulsividad.
EP3579826B1 (en) Methods of treating cdkl5 disorders with the compound ov329
ES2515092T3 (es) Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
ES2930899T3 (es) Monohidrato de gaboxadol en el tratamiento del tinnitus
JP7387179B2 (ja) 発達障害の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸および関連化合物、（１ｓ，３ｓ）－３－アミノ－４－（ジフルオロメチリデン）シクロペンタン－１－カルボン酸ならびにビガバトリンの使用
Kokki Current management of pediatric postoperative pain
JP2021521103A (ja) 物質使用障害の処置におけるガボキサドールの使用
US11771671B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
CN116801863A (zh) 右美托咪定治疗方案
CN112930182A (zh) 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途
US12303503B1 (en) Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain
KR20210038843A (ko) 주의력 결핍 과잉 행동 장애를 치료하는 방법
WO2020018779A1 (en) Use of phenylethylidenehydrazine to treat seizure disorders, developmental disorders, neurological disorders, behavioral disorders and addiction
Margoles Medications that may be useful in the management of patients with chronic intractable pain
US10265300B2 (en) Methods of treating seizure disorders
IL324602A (en) Rapid induction with monthly buprenorphine sustained-release injection
HK40017808A (en) Methods of treating seizure disorders
HK40015478A (en) Use of gaboxadol in the treatment of tinnitus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230627